Sensyne Health PLC NED Appointment (3143C)
June 18 2021 - 1:00AM
UK Regulatory
TIDMSENS
RNS Number : 3143C
Sensyne Health PLC
18 June 2021
Board Appointment
Dr Ian Hudson to join as Independent Non-Executive Director
Oxford, U.K. 18 June 2021: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company"), the Clinical AI company, today
announces the appointment of Dr Ian Hudson to the Board as
Independent Non-Executive Director with effect from 28 June
2021.
Dr Hudson has extensive knowledge of the healthcare and
pharmaceutical sector, having served as Chief Executive of the UK's
Medicines and Healthcare Products Regulatory Agency ("MHRA")
between 2013 and 2019. Prior to this, he was the MHRA's Licensing
Director, responsible for most of the agency's medicines licensing
activities.
Before joining the MHRA, Dr Hudson held various senior roles at
SmithKline Beecham, working for more than a decade in clinical
research and development. Dr Hudson is currently serving as Senior
Advisor, Integrated Development for the Bill and Melinda Gates
Foundation, working in areas that include optimizing clinical
studies and strengthening regulatory systems in low-resource
regions, as well as providing regulatory input to teams working on
malaria, polio, and COVID-19 drugs.
In 2020, he was awarded an OBE for Services to Healthcare,
received a Faculty of Pharmaceutical Medicine President's medal for
contribution to pharmaceutical medicine, and was named a Global
Fellow in Medicines Development by the International Federation of
Associations of Pharmaceutical Physicians and Pharmaceutical
Medicine.
Professor Sir Bruce Keogh, Non-Executive Chairman of Sensyne,
said : " I am thrilled to welcome Ian to the Board at such an
important time for Sensyne. Ian's experience will be a great asset
as we build an innovative and world class clinical artificial
intelligence company."
Dr Ian Hudson, Independent Non-Executive Director of Sensyne,
said: "The COVID-19 pandemic has demonstrated how important
clinical AI is to the effective management of health. Sensyne has
been at the forefront of this trend, applying ethical AI to
improving healthcare and life sciences research and I'm looking
forward to supporting the company on what is an increasingly global
journey."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Dr Ian Robert Burton Hudson (age 62)
There is no further information required to be disclosed
pursuant to Schedule Two paragraph (g) of the AIM Rules in respect
of Dr Hudson.
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com ) +44 (0) 330 0581845
Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive
Officer
Richard Pye, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint Broker) + 44 (0) 20 7418900
Dr Christopher Golden
James Steel
Oliver Jackson
Liberum (Joint Broker) + 44 (0) 201002000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications +44 (0) 7780600290
Mary-Jane Elliott
Jessica Hodgson
Davide Salvi
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in
partnership with global healthcare organisations to improve patient
care and accelerate the discovery and development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKDLFFFQLXBBX
(END) Dow Jones Newswires
June 18, 2021 02:00 ET (06:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024